Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-DOTA-TATE Treatment in Patients With Somatostatin Receptor Positive Tumours
NCT01876771Phase 2Suspended
- Sponsor
- American Health Staffing Group
- Start
- Apr 2014
- Primary completion
- Dec 2042
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by American Health Staffing Group. Started Apr 2014; status: suspended.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT01876771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01876771.